Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Other Non-Current Assets (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Other Non-Current Assets for 7 consecutive years, with $6.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Non-Current Assets fell 18.03% to $6.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $6.7 million, a 18.03% decrease, with the full-year FY2025 number at $6.7 million, down 18.03% from a year prior.
  • Other Non-Current Assets was $6.7 million for Q4 2025 at Beam Therapeutics, roughly flat from $6.7 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $15.4 million in Q2 2023 to a low of $6.2 million in Q2 2024.
  • A 5-year average of $10.2 million and a median of $9.3 million in 2023 define the central range for Other Non-Current Assets.
  • Peak YoY movement for Other Non-Current Assets: increased 20.99% in 2023, then plummeted 60.1% in 2024.
  • Beam Therapeutics' Other Non-Current Assets stood at $12.7 million in 2021, then rose by 0.06% to $12.8 million in 2022, then tumbled by 31.64% to $8.7 million in 2023, then dropped by 6.59% to $8.1 million in 2024, then decreased by 18.03% to $6.7 million in 2025.
  • Per Business Quant, the three most recent readings for BEAM's Other Non-Current Assets are $6.7 million (Q4 2025), $6.7 million (Q3 2025), and $6.6 million (Q2 2025).